-
Kizdar net |
Kizdar net |
Кыздар Нет
- Immunotherapy developer Agenus ($AGEN), looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline ($GSK) to grab $115 million in exchange for royalties it once held on an adjuvant for GSK's malaria and shingles vaccines.
www.fiercepharma.com/r-d/agenus-trades-adjuvant-rights-to-gsk-for-115m-to-bo… - People also ask
Combo may offer route back for Agenus' cervical cancer drug
WEBJan 23, 2023 · Fifteen months after the FDA blindsided Agenus with a decision not to offer accelerated approval for the cervical cancer drug balstilimab, the biotech is back with …
See results only from fiercebiotech.comAgenus lays off 25%, sidelin…
Agenus hopes the layoffs and pipeline narrowing will together save $40 million …
Agenus: 2024 May Finally Be The Year For A Major Turnaround
WEBJan 18, 2024 · Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple …
UPDATE: Agenus withdraws cervical cancer application
WEBOct 22, 2021 · Agenus claims the FDA granted full approval to Merck's Keytruda in cervical cancer too quickly, blocking its chances of getting accelerated approval for balstilimab. …
Agenus Announces Reverse Stock Split of Common Stock
WEBApr 5, 2024 · Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have …
Agenus lays off 25%, sidelines programs to focus on cancer combo
WEBAug 23, 2023 · Agenus hopes the layoffs and pipeline narrowing will together save $40 million that can be redirected to accelerate the lead program’s development as it gears …
Agenus Inc. (AGEN) Stock Forum & Discussion - Yahoo Finance
WEBFind the latest Agenus Inc. (AGEN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Future of Agenus’ Immunotherapy Combo Uncertain as FDA
WEBJul 18, 2024 · Agenus revealed Thursday that the FDA has “ advised against ” applying for accelerated approval for its investigational immunotherapy combination regimen …
With Merck blocking its path, a small biotech reroutes, to the …
WEBOct 22, 2021 · Agenus, a small biotech, decided to pull back its application for balstilimab, a PD-1 inhibitor, after the FDA recommended it in light of Merck's Keytruda approval. The …
Bristol Myers to pay up to $1.56 bln to develop, sell Agenus’s …
WEBMay 18, 2021 · Drugmaker Bristol Myers Squibb (BMY.N) will pay biotech firm Agenus Inc (AGEN.O) up to $1.56 billion to exclusively develop and commercialize its experimental …
Agenus' Data Release And MiNK IPO Should Lead To …
WEBAug 25, 2021 · If oncology companies are valued at ~5X their products' estimated peak sales, AGEN could be worth ~$20Billion (~$80/share+) in a buyout after approval by the FDA based solely on 1181/Bal's...
Why Agenus Stock Is Crushing It Today | The Motley Fool
WEBMar 2, 2022 · Shares of clinical-stage immunotherapy company Agenus ( AGEN -0.36%) were up by a healthy 18% as of 1:09 p.m. ET on Wednesday. Investors are bidding up …
Agenus Inc. (AGEN) Latest Stock News & Headlines - Yahoo …
WEBGet the latest Agenus Inc. (AGEN) stock news and headlines to help you in your trading and investing decisions.
Agenus (AGEN) Stock Price, News & Analysis - MarketBeat
WEB2 days ago · Should You Buy or Sell Agenus Stock? Get The Latest AGEN Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.
Agenus trades adjuvant rights to GSK for $115M to bolster …
WEBSep 10, 2015 · Immunotherapy developer Agenus, looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline to grab …
Agenus Shares Blast Higher on Deal with Bristol Myers
WEBMay 18, 2021 · Agenus shares skyrocketed Tuesday after Bristol Myers Squibb agreed to pay the pharmaceutical company up to $1.56 billion for the rights to its immuno-cancer …
Positive Outlook for Agenus: Promising Clinical ... - Markets Insider
WEBNov 8, 2023 · Mayank Mamtani issued a buy rating for Agenus due to a combination of factors. Following the release of the company’s 3Q23 financial results, Mamtani has …
Agenus: A Would-Be Rockstar Held Back By Middling Financials
WEBFeb 27, 2024 · Agenus' phase 2 trial of botensilimab in colorectal cancer is fully enrolled, with a mid-year 2024 readout likely. Read why I'm bullish on AGEN stock.
Biotech layoffs 2023: Lexington's Agenus lays off 91 as it narrows ...
WEBAug 23, 2023 · Agenus plans to submit data to the U.S. Food and Drug Administration for a potential approval in colorectal cancer next year. Agenus had $157.6 million cash on …
Agenus Inc (AGEN) Stock Price Today, Quote, Latest …
WEBTrack Agenus Inc (AGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the …
Agenus to Receive $25 Million Milestone Payment from Bristol …
WEBDec 11, 2023 · Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing …
FDA wrecks Agenus’ accelerated approval plan, triggering push …
WEBJul 18, 2024 · The FDA has scotched Agenus’ plans to seek accelerated approval for a colorectal cancer combination, prompting the biotech to look into partnering to fund the …
Bristol Myers Squibb - Agenus and Bristol Myers Squibb …
WEBMay 18, 2021 · NEW YORK & LEXINGTON, Mass.-- (BUSINESS WIRE)-- (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a …
Agenus to lay off 25% of staff, trim pipeline in cancer drug push
WEBAug 23, 2023 · Agenus has become the latest biotechnology company to turn to layoffs this year, announcing Wednesday a plan to reduce its workforce by 25% and significantly …
Skip to content